Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S241656 (BDTX-4933) in Advanced Malignancies with RAS/MAPK Mutations
NCT05786924Phase 2Recruiting
- Sponsor
- Servier
- Start
- Apr 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of bdtx-4933 in non-small cell lung cancer (NSCLC), gastrointestinal cancer, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), biliary tract cancer (BTC), sponsored by Servier. Started Apr 2023; status: recruiting.
02
Drugs
bdtx-4933
03
Conditions
non-small cell lung cancer (NSCLC)gastrointestinal cancerpancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05786924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786924.